Donate

Industry NewsThe following is an excerpt from a press release from Spark Therapeutics. Read the press release in its entirety here.


Spark Therapeutics , a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per share in an all-cash transaction. This corresponds to a total equity value of approximately $4.8 billion on a fully diluted basis, inclusive of approximately $500 million of projected net cash expected at close.

Under the terms of the merger agreement, Roche will promptly commence a tender offer to acquire all outstanding shares of Spark鈥檚 common stock, and Spark will file a recommendation statement containing the unanimous recommendation of the Spark board that Spark shareholders tender their shares to Roche.

鈥淎s the only biotechnology company that has successfully commercialized a gene therapy for a genetic disease in the U.S., we have built unmatched competencies in the discovery, development and delivery of genetic medicines. But the needs of patients and families living with genetic diseases are immediate and vast,鈥 said聽Jeffrey D. Marrazzo, chief executive officer of聽Spark Therapeutics. 鈥淲ith its worldwide reach and extensive resources, Roche will help us accelerate the development of more gene therapies for more patients for more diseases and further expedite our vision of a world where no life is limited by genetic disease.鈥

鈥淪park Therapeutics鈥 proven expertise in the entire gene therapy value chain may offer important new opportunities for the treatment of serious diseases,鈥 said Severin Schwan, chief executive officer of Roche. 鈥淚n particular, Spark鈥檚 hemophilia聽A program could become a new therapeutic option for people living with this disease. We are also excited to continue the investments in Spark鈥檚 broad product portfolio and commitment to Philadelphia as a center of excellence.鈥

Spark Therapeutics will continue its operations in Philadelphia as an independent company within the Roche Group.

 

Read the press release in its entirety here.聽

Facebook Comments


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.